September 18th 2021
Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.
New Frontier for Genomics: Radiotherapy in Early Breast Cancer
April 8th 2020By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.
ctDNA Provides Prognostic and Predictive Value in Early-Stage Breast Cancer
April 3rd 2020Circulating tumor DNA can be used as a predictive measure of response to neoadjuvant chemotherapy and inform overall prognosis in patients with early-stage breast cancer, providing information that can be used to tailor treatment.
Immunotherapy Biomarker Testing Depends on Tumor Type
April 1st 2020A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.